The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | Response rates to salvage therapies following anti-BCMA CAR-T failure in patients with myeloma
Jaromir Tomasik, Medical University of Warsaw, Warsaw, Poland, provides insight into a meta-analysis of response rates to salvage therapies in patients with multiple myeloma (MM) who experienced anti-BCMA CAR-T failure. He discusses the potential use of alternative CAR-T antigen targets and bispecific antibodies as salvage therapies in this patient population and highlights the need for longer-term follow-up data. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We were particularly interested in how to treat patients who failed anti-BCMA CAR T-cell therapy because you know if somebody fails CAR-T, the prognosis is dismal. So we wanted to just quantify what could be like a response rate to any subsequent salvage therapy and actually, this study was challenging again due to some data limitations; however, we managed to establish some benchmarks and overall I would say the best candidates are other CAR T-cell therapies targeting different antigens or maybe even the same one and also bispecific antibodies and they showed pretty decent response rates above 50%, approaching 70% for bispecifics and for CAR T-cells, even 80 or 90%...
We were particularly interested in how to treat patients who failed anti-BCMA CAR T-cell therapy because you know if somebody fails CAR-T, the prognosis is dismal. So we wanted to just quantify what could be like a response rate to any subsequent salvage therapy and actually, this study was challenging again due to some data limitations; however, we managed to establish some benchmarks and overall I would say the best candidates are other CAR T-cell therapies targeting different antigens or maybe even the same one and also bispecific antibodies and they showed pretty decent response rates above 50%, approaching 70% for bispecifics and for CAR T-cells, even 80 or 90%. But the question is whether the responses are stable, perhaps not, as we know patients with multiple myeloma tend to relapse quickly, and we just wanted to show what’s possibly the best solution for further proceedings. We also found out that some therapeutics are not working well in this setting. We had some not-the-best reports on belantamab. Also, other agents didn’t perform well, so perhaps for these patients, another line is bispecifics or CAR T-cells. It depends on the site a patient is in. But generally, we did our best to extract some kind of benchmark in this setting. And while longer follow-up is not available to do a meta-analysis, at least at the time we were extracting it, we wanted to provide something and we provided response rates. I know that some people may not like it because it’s a very short endpoint after the treatment administration, but this is what we have.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
